Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma

Lymphoma, Non-Hodgkin Clinical Trial

Official title:

A Phase I/II Institutional Study of Abraxane in Recurrent and Refractory Lymphoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01555853
• Other study ID #: 201204071
• Status: Terminated
• Phase: Phase 1
• First received: March 13, 2012
• Last updated: December 5, 2016
• Start date: July 2012
• Est. completion date: June 2016

Study information

• Verified date: December 2016
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This phase I/II trial studies the side effects, maximum tolerated dose, and effectiveness of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating patients with recurrent or refractory Hodgkin or B-cell non-Hodgkin lymphoma. More effective and well tolerated therapies are needed to treat patients with relapsed and refractory lymphomas. Nab-paclitaxel combines a chemotherapeutic agent with a protein which may increase the anticancer drug concentration in the tumor while reducing toxic effects in normal tissue and may be an effective treatment for lymphoma.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 20
• Est. completion date: June 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient must have histologically confirmed B-cell non-Hodgkin lymphoma or classical Hodgkin lymphoma:

• Diffuse large B-cell lymphoma (including transformed large cell lymphoma and primary mediastinal B cell lymphoma)

• Mantle cell lymphoma

• Burkitt's lymphoma

• Follicular lymphoma

• Small lymphocytic lymphoma

• Marginal zone lymphoma

• Lymphoplasmacytic lymphoma

• Classical Hodgkin lymphoma (including nodular sclerosis, mixed cellularity, lymphocyte rich, and lymphocyte deplete)

• Patient must have measurable disease, defined as the presence of = 1 lymph node or tumor mass measuring = 1 cm in a single dimension as assessed by CT or MRI.

• Patient must have had prior treatment with = 2 chemotherapy or chemo-immunotherapy regimens. Prior autologous stem cell transplant is allowed, and prior allogeneic stem cell transplant is allowed as long as the patient has recovered from acute toxicities and is off immunosuppression without evidence of graft versus host disease (GVHD).

• Patient must be = 18 years of age.

• Patient must have an ECOG performance status = 2.

• Patient must have adequate bone marrow reserve at the time of therapy initiation, defined as ANC = 1.0 x 109/L and platelets = 50 x 109/L.

• Patient must have adequate hepatic function, defined as total bilirubin = 1.5 x ULN and AST/ALT = 3 x ULN.

• Patient must have adequate renal function, defined as serum creatinine = 2.0 x ULN.

• Patient must have recovered from any acute toxicities associated with prior therapy to = grade 1.

• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.

• Patient (or legally authorized representative, if applicable) must be able to understand and willing to sign an IRB approved written informed consent document.

• Both men and women and members of all races and ethnic groups are eligible for this trial.

Exclusion Criteria:

• Patient must not have nodular lymphocyte predominant Hodgkin lymphoma subtype.

• Patient must not have a history of a non-lymphoma malignancy except for the following: adequately treated localized basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder cancer, localized prostate cancer, any adequately treated stage I or stage II cancer currently in complete remission, or any other cancer in complete remission for at least 5 years.

• Patient must not be receiving any other investigational agents, and must not have taken any other investigational agents within = 3 weeks of study entry chemotherapy, immunotherapy, radiotherapy, and/or investigational agents while on study.

• Patients with Hodgkin's lymphoma must not otherwise be eligible for treatment with brentuximab vedotin.

• Patient must not have central nervous system or leptomeningeal lymphoma.

• Patient must not have with history of allergic reactions attributed to compounds of similar chemical or biologic composition to Abraxane.

• Patient must not have any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Patient must not be pregnant and/or breastfeeding.

• Patient must not be known to be HIV-positive.

• Patient must not have any pre-existing peripheral neuropathy > grade 1.

• Patient must not have received any chemotherapy, immunotherapy, and/or investigational agents and/or radiotherapy < 3 weeks prior to starting study drug.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hodgkin Disease
• Lymphoma
• Lymphoma, Non-Hodgkin

Intervention

Drug:
• Abraxane

Locations

Country	Name	City	State
United States	St. Louis University School of Medicine	St. Louis	Missouri
United States	Washington University School of Medicine	St. Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase I: Maximum tolerated dose (MTD) of Abraxane in patients with recurrent or refractory lymphoma	Graded and described using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.	28 days (completion of cycle 1) for all patients in Phase I portion	Yes
Primary	Phase I: Dose-limiting toxicities (DLTs) of Abraxane in patients with recurrent or refractory lymphoma	Graded and described using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4	28 days (completion of cycle 1)	Yes
Primary	Phase II: Overall response rate (CR + PR)		24 weeks (end of study)	No
Secondary	Phase I: Toxicity associated with Abraxane		28 weeks (30 days after completion of study treatment)	Yes
Secondary	Phase II: Time to progression.	Response and progression will be recorded with each imaging evaluation according to the 2007 revised response criteria for malignant lymphoma by Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.	24 weeks (end of study)	No
Secondary	Phase II: Duration of remission		24 weeks (end of study)	No
Secondary	Phase II: Overall survival.		3 years	No
Secondary	Phase II: Clinical benefit (CR + PR + SD)		24 weeks (end of study)	No

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine